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Abstract
Background: Comel-Netherton syndrome (NS) is a rare autosomal disease, char-
acterized by severe skin disease, hair shaft defects, atopic diathesis, and increased 
susceptibility for skin infections. Since patients with NS suffer from recurrent infec-
tions, it has been hypothesized that an underlying immunodeficiency attributes to 
this. Here, we studied clinical and immunological characteristics of the cohort of NS 
patients in the Netherlands in order to identify whether potential immunodeficien-
cies result in the increased risk of infectious complications.
Methods: Phenotypes were scored for severity of skin condition, specific hair shaft 
defects, atopy, and recurrent infections. Patients’ blood samples were collected 
for quantification of serum immunoglobulin (Ig) levels, specific antibodies against 
Streptococcus pneumoniae, and allergen-specific IgE, as well as detailed immunophe-
notyping of blood leukocyte and lymphocyte subsets by flow cytometry.
Results: A total of 14 patients were included with age range 3-46 years and varying 
degrees of skin involvement. All patients presented with atopic symptoms (food al-
lergy, n = 13; hay fever, n = 10; asthma, n = 7). Recurrent skin infections were common, 
particularly in childhood (n = 12). Low levels of specific antibodies against S pneumo-
niae were found in 10 of 11 evaluated patients. Detailed immunological analysis was 
performed on 9 adult patients. Absolute numbers of lymphocyte subsets and serum 
immunoglobulin levels were all within normal ranges.
Conclusion: Multidisciplinary evaluation of our national cohort showed no evidence for 
a severe, clinically relevant systemic immunodeficiency. Therefore, we conclude that in 
Dutch NS patients the increased risk of infections most likely results from the skin barrier 
disruption and that increased allergen penetration predisposes to allergic sensitization.
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1  | INTRODUC TION
Comel-Netherton syndrome (NS) (OMIM #256500) is a severe geno-
dermatosis typically characterized by chronic inflammatory skin le-
sions (ichthyosis and scaly erythroderma), specific hair shaft defects 
(trichorrhexis invaginata), and atopic diathesis with elevated serum 
IgE levels.1,2 The disease is caused by variants in the SPINK5 gene 
(serine protease inhibitor of kazal type 5) encoding LEKTI (lymphoe-
pithelial kazal type-related inhibitor), which is expressed in the strat-
ified epithelium of the skin, the mucosa, and the Hassal corpuscles 
of the thymus.3-6
The consequence of LEKTI deficiency is a loss of inhibition of 
serine proteinases such as plasmin, trypsin, subtilisin A, cathepsin 
G, and elastase.7-11 This particularly leads to unopposed activity of 
kallikrein-related peptidase 5 (KLK5), which activates KLK7, KLK14, 
and elastase 2 (ELA2).12-14 In the skin, this leads to increased degra-
dation of corneodesmosomal cadherins through increased degrada-
tion of desmoglein 1, increased desmosome cleavage, and reduced 
filaggrin proteolytic processing.15-17 The result is an abnormal skin 
homeostasis and detachment of the stratum corneum, which con-
tributes to a defective skin barrier and thereby enabling microbe 
and allergen penetration.18 KLK5 also activates protease-activated 
receptor 2 (PAR-2) which is expressed on the surface of keratino-
cytes.19 Observations from SPINK5 knockout mouse embryos in-
dicate a KLK5-PAR2 cascade, leading to enhanced production of 
thymic stromal lymphopoietin (TSLP), a T-helper 2 (Th2)-related cy-
tokine, enhancing the allergic predisposition.20 Furthermore, PAR-2 
leads to increased expression of TNF-α, IL-8, and ICAM-1, thereby 
augmenting an inflammatory process.21
The effects of defective LEKTI expression in the thymus and its 
effect on T-cell maturation are less well-described. However, apart 
from dermal and allergic inflammation, the disease has also been as-
sociated with immunodeficiency and increased susceptibility to skin, 
respiratory tract, and systemic infections.22-25 Although recurrent skin 
infections with Staphylococcus aureus can be related to altered skin 
homeostasis, some have attributed these observations to intrinsic im-
mune defects, with improvement after intravenous immunoglobulin 
treatment.22 Described immune defects include decreased numbers 
of natural killer (NK) cells, an immature phenotype of NK cells with re-
duced lytic function, reduced numbers of memory B cells, and reduced 
responses to pneumococcal vaccinations.22-26 Although a premature 
senescent state of T cells has been proposed, there have been no re-
ports on dysfunctional T-cell properties. This is likely due to the fact 
that NS is a rare disease, and the described patient cohorts are small 
(mostly 2-9 patients) and mainly consist of children.
To examine the potential of immunodeficiency in NS, we actively 
recruited all known patients in the Netherlands for detailed clinical 
and immunological examinations including skin phenotype, allergic 
manifestations, and blood leukocyte immunophenotyping.
2  | METHODS
2.1 | Study design and patient characteristics
The study was designed as a cross-sectional study. All known 
16 patients with NS in the Netherlands were invited to partici-
pate in the study. Patients were actively recruited through the 
G R A P H I C A L  A B S T R A C T
Fourteen patients with Netherton disease with varying degrees of skin involvement were evaluated for clinical and immunological 
characteristics. Multidisciplinary evaluation, including blood immunophenotyping, shows no evidence for a severe, clinically relevant 
systemic immunodeficiency. Increased risk of infections in Netherton patients most likely results from the skin barrier disruption and 
increased allergen penetration predisposes to allergic sensitization.
Abbreviations: ELA, elastase; ICAM, intercellular adhesion molecule; KLK, kallikrein-related peptidase; LEKTI, lympho-epithelial kazal type 
related inhibitor; PAR, protease-activated receptor; SPINK5; serine protease inhibitor of kazal type 5; TSLP, thymic stromal lymphopoietin
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Erasmus MC University Medical Centre Rotterdam, an acknowl-
edged national expert center for patients with NS, through the 
patient association and by social media. Patients were diag-
nosed based on the presence of germline variants in SPINK5, 
LEKTI deficiency in skin biopsy, and/or trichorrhexis invaginata 
(ISRCTN12831121).27 Patients and controls were included after 
obtaining written informed consent and with approval of the 
Medical Ethical Committee of the Erasmus MC (MEC-2013-026), 
which complies with the Helsinki declaration. Control blood sam-
ples were obtained from healthy volunteers among department 
staff (MEC-2016-022).
All patients completed questionnaires about their medical 
well-being, including medical history, (daily) medication use, daily 
skin appearance, growth rate, frequency of infections, hospital ad-
missions, and (food) allergies. Subsequently, patients were invited 
for blood sampling and a multidisciplinary evaluation by a (pediat-
ric) dermatologist and (pediatric) immunologist of our Netherton 
team.
Detailed immunological evaluation was performed in 9 out of 14 
patients. Four of the five patients not included were children who 
were excluded because patient numbers in these age groups were 
too low for reliable statistical analysis. One adult patient was ex-
cluded who did not consent to blood collection. For specific flow 
cytometric analysis of the immune cells, a control group (n = 27) was 
included to determine assay-specific reference values.
2.2 | Skin assessment and recurrent infections
To objectively score skin lesions, the body surface area (BSA in %), 
the Investigator's Global Assessment for NS (IGA-NS) and the total 
lesional sign score (TLSS) were used (Table S1).28-30
Definitions of recurrent infections were based on the 10 warning 
signs for primary immunodeficiency stated by the working party of 
ESID (European Society for Immunodeficiencies)31 and are defined 
as follows: recurrent skin infections >1 per year; recurrent respira-
tory tract infections >2 per year for adults, >6 per year for children; 
recurrent ear nose and throat (ENT) infections >4 per year; and re-
current gastrointestinal tract infections >1 per year.
2.3 | Immunoglobulin serology
Specific IgE for inhalation and food allergens were determined 
using ImmunoCAP and/or the Immuno Solid-phase Allergen 
Chip (ImmunoCAP ISAC, Phadia), according to manufacturer's 
instructions.
Total IgM, IgG, and IgA serum levels were measured by im-
munonephelometry with a Siemens BN II nephelometer accord-
ing to manufacturer guidelines. Specific antibody titers against 
Streptococcus pneumoniae were analyzed using a Luminex assay ac-
cording to a protocol adopted from Borgers et al32
2.4 | Flow cytometric immunophenotyping of 
blood leukocytes
Absolute numbers of granulocytes, monocytes, lymphocytes, 
and NK cells (CD16+/CD56+), T cells (CD3+), and B cells (CD19+) 
were obtained with a diagnostic lyse-no-wash protocol using 
commercial Trucount tubes (BD Biosciences). For detailed 11-
color flow cytometry, red blood cells were lysed with NH4Cl 
prior to incubation of 1 million nucleated cells with antibody 
cocktails for 15 minutes at room temperature in a total volume 
of 100 µL.33 After preparation, cells were measured on a 4-laser 
LSRFortessa flow cytometer (BD Biosciences) using standardized 
settings.34 Data were analyzed with FACSDiva software V8.0 
(BD Biosciences).
2.5 | Statistical analyses
Frequencies and absolute cell numbers were assumed a non-Gauss-
ian distribution. All results are expressed as median values with 
interquartile range if applicable. Results were analyzed using the 
nonparametric Mann-Whitney U test; all tests were two-tailed, and 
P values < 0.05 were considered statistically significant. Statistical 
analysis was performed using GraphPad Prism software, version 6 
(GraphPad Software).
3  | RESULTS
3.1 | Clinical characteristics of the patient cohort
For the present study, all known patients with NS in the 
Netherlands (n = 16) were invited; however, due to private cir-
cumstances two patients refused to participate. The included 14 
patients (6 males and 8 females) ranged in age from 3 to 46 years 
(median, 24 years), and included four children, which were all fe-
male (Table 1).
Ten patients were born with generalized erythroderma and two 
patients developed erythroderma within several hours after birth 
(Table 1). The skin severity varied between patients: Six patients had 
an affected body surface area (BSA) of 100% and 5 patients of >50% 
with a median Investigator Global Assessment (IGA)-NS score of 3 
(IQR 3-4). All patients had trichorrhexis invaginata. Seven out of 14 
patients noticed improvement of their skin over time with a median 
of 6.5 years. All patients reported daily invalidation on a scale of 
1-10 with a median of 5 (IQR 3-6), a daily pain numerical rating scale 
(NRS) median of 7.0 (IQR 2.8-8.0), and pruritus NRS median of 4.0 
(IQR 3.0-7.5; Table S2).
When compared to the normal growth chart for children and the 
average height for adults (data of the Netherlands Organization for 
Applied Scientific Research), patients seemed to be smaller than the 
average population (Table S3).
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3.2 | Atopic syndrome
Ten out of 14 patients had self-reported hay fever, and 7 patients 
had self-reported asthma. Thirteen out of 14 patients reported reac-
tions to food (especially nuts, cow milk, eggs, and fish) with symp-
toms occurring within two hours after intake (nausea, stomach pain, 
or edema of the nasopharynx) (Table 1 and Table S4). Most patients 
had refused double-blind food provocation tests due to severe acute 
reactions. Additional laboratory tests were performed to confirm IgE 
sensitization to inhalant and food allergens. All 10 patients who were 
tested had IgE sensitization to food allergens (Table S4). Eleven out 
of the 12 tested patients had elevated total immunoglobulin E (IgE) 
above 100 IE/mL, and one patient had a normal IgE level of 22 IE/
mL (Table 1).
3.3 | Treatment
All 14 patients used emollients for daily skin treatment, and 12 out of 
14 patients needed topical corticosteroids, ranging from hydrocor-
tisone acetate to clobetasol propionate. One patient intermittently 
used tacrolimus ointment based on the severity of complaints, and 
one patient used coal tar. Three patients received treatment with 
oral antihistamines, and all received treatment with inhalation medi-
cation. At the time of study inclusion, none of the patients received 
systemic immunosuppressive treatment.
3.4 | Immunological evaluation
A significant number of infections were reported in 13 out of 
14 patients, particularly recurrent skin infections being a com-
mon problem, with a median of 4.1 infections requiring treat-
ment with antibiotics every year (IQR: 2.8-5.0; Table 2). Seven 
patients reported recurrent ENT infections in early childhood for 
which repetitive antibiotic treatments were required. In one pa-
tient, recurrent ENT infections persisted throughout adulthood. 
Several patients reported the need of regular cleaning of the ex-
ternal auditory meatus every 4 weeks to prevent external ear 
infections. Before the age of 6 years, patients did not report fre-
quent respiratory infections. Of the 12 patients above the age of 
6 years, 7 patients suffered from recurrent skin infections in the 
previous 12 months. One patient reported recurrent gastrointes-
tinal infections as a child, and none reported these during adult-
hood. Similarly, one patient reported severe systemic infections 
during childhood, but none were reported during adulthood. No 
patients described a period of persistent fever after vaccinations 
(Table 2).
None of the 13 tested patients showed an overt antibody de-
ficiency. All patients had normal to high levels of IgG and IgA, and 
only 2 patients had reduced IgM serum levels (Table 2). In 10 out of 
11 tested patients, levels of specific antibodies against S pneumoniae 
were low (Table 2).
3.5 | Patients with NS have higher numbers of 
granulocytes
Blood leukocytes and their subsets were studied in 9 of the 10 
adult patients (Figure 1). One patient had a leukocyte count above 
the normal range, which was caused by an elevated granulocyte 
count. Compared with the healthy individuals, patients with NS 
had a significantly higher granulocyte count (P = .04). Absolute 
numbers of total lymphocytes and monocytes were in the normal 
range. Within the granulocyte subset, mainly the numbers of neu-
trophils seemed higher, although this was not significantly differ-
ent from controls. Two patients had an increased eosinophil count. 
All patients had a normal basophil count, yet the median count 
was significantly lower than that of the control group (P = .02). 
Numbers of plasmacytoid dendritic cells (pDCs) were dramati-
cally decreased in the patient group (P < .001). Within the lym-
phocyte subset, one patient had an increased B-cell count and one 
patient had an increased T-cell count, yet as a group the median 
T-cell count was significantly lower than that of healthy controls 
(P = .04). In our study cohort, NK-cell numbers were quite diverse, 
but not statistically different from the control group. Still, one pa-
tient had increased NK-cell numbers, whereas two patients had 
reduced NK-cell numbers.
3.6 | Patients with NS have lower IgM-only memory 
B-cell numbers and increased IgE+ CD27− memory 
B-cell numbers
Within the B-cell compartment, we studied naive, memory, and 
effector B-cell subsets (Figure 2). Absolute numbers of naive 
B-cell subsets (transitional B cells and naive mature B cells) 
were comparable to that of healthy controls. In the memory 
compartment, median cell numbers of IgM-only memory B cells 
(IgM+ IgD− CD27+) were significantly lower than that of healthy 
controls (P = .03), whereas cell numbers of other memory B-cell 
subsets (IgM+ IgD+ CD27+ natural effector B cells, IgG+ and IgA+ 
memory B cells) were comparable to those of healthy controls 
(Figure 2A). In contrast, the median cell number of IgE + CD27− 
memory B cells was significantly higher in the patient group 
(P = .01; Figure 2B). Plasma blast numbers seemed much lower 
in patients with NS. One patient had a high plasma blasts count; 
therefore, as a group there was no significant difference between 
patients and controls.
3.7 | Patients with NS have lower Th1-cell numbers
Since LEKTI is highly expressed in the thymus, the primary organ 
for T-cell development, we performed detailed analysis of the T-cell 
compartment (Figure 3). Although total T-cell numbers were signifi-
cantly lower in the total group of patients as compared to controls, 
all patients but one had T-cell numbers still within the normal range. 
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In line with this, total CD4+ and CD8+ T cells, as well as numbers of 
naive, central memory, and effector memory subsets within CD4+ 
and CD8+ T cells, were not different between patients and controls 
(Figure 3A and 3).
Within the T-helper cells, numbers of Th1 cells were significantly 
lower in patients with NS, whereas Th2 cell numbers were not af-
fected (Figure 3C). Th17 nor regulatory T-cell numbers were differ-
ent between patients and controls (Figure 3C).
4  | DISCUSSION
In this case series, 14 of the 16 known NS patients in the Netherlands 
were evaluated for their clinical phenotypes, atopic diathesis, and im-
munological characteristics. To our knowledge, this is the first described 
national NS patient cohort. Their history and clinical presentation are an 
illustration of the wide spectrum of disease in patients with NS, espe-
cially concerning clinical features, disease severity, and follow-up.26
F I G U R E  1   Absolute numbers of leukocytes and leukocyte subsets in healthy individuals and in adult patients with NS. Each symbol 
represents an individual with red lines indicating median values. Normal ranges are depicted in gray shades. Statistics, Mann-Whitney U test; 
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Immunological evaluation of our patients showed no evidence 
for a severe, clinically relevant systemic immunodeficiency, even in 
the more severely affected patients, which is in contrast to other 
studies.22,26 Although low titers of specific antibodies against 
S pneumoniae were measured, the current evaluation could not con-
firm the presence of a clinically relevant humoral immunodeficiency, 
based on the fact that patients did not suffer from an increased num-
ber of severe infections that can be contributed to these findings.22 
Functional assays evaluating potential NK-cell disturbances were 
not performed, but NK-cell numbers were not affected. This does 
not explain the difference between our observations with previous 
studies; however, an explanation might be that due to the national 
recruitment we experienced less selection bias resulting in more di-
versity in our cohort, hence giving a better reflection of the whole 
spectrum of NS, at least in the Netherlands. The dramatically de-
creased numbers of pDCs can be explained by the fact that these 
cells are highly sensitive to (cutaneous) corticosteroid therapy.35 
One patient used tacrolimus ointment, which has been reported to 
result in increased systemic absorption in children with Netherton 
disease.36 The patient in our cohort was an adult with intermittent 
use, for whom no data on systemic side effects were acquired.
All patients in the Dutch cohort were below the age of 50 years. 
We hypothesized that NS patients may have an accelerated aging 
of the immune system due to the severe skin barrier defect and/or 
by the defective LEKTI expression in the thymus, which may result 
in a lower life expectancy. This was not confirmed by our data as 
the numbers of naive T cells as well as effector T-cell subsets were 
within normal range. This study does not explain the young age of 
the adult patients.
The increased manifestation of skin and ENT infections, espe-
cially in childhood, observed in our cohort, may still imply an im-
munodeficiency according to the guidelines of European Society for 
Immunodeficiencies (ESID),37 although in our cohort it is not known 
by which pathogens the infections were caused. We did observe 
lower numbers of IgM-only memory B cells (IgM+ IgD− CD27+); 
however, this has not been associated with immunodeficiency. 
Natural effector (IgM+ IgD+ CD27+) B cells are responsible for nat-
ural antibodies, whereas lower numbers of switched memory B cells 
(CD27+ IgM− IgD−) are found in patients with primary antibody de-
ficiencies, including common variable immune deficiency (CVID).38 
In our patients, switched memory B-cell numbers were within the 
normal range. Moreover, no hypogammaglobulinemia was found in 
NS patients. The clinical relevance of the decreased IgM-only mem-
ory B cells remains therefore undetermined.
The recurrent ear infections in children and adults with NS could 
well be caused by obstruction of the external auditory canal as a 
result of excessive skin scaling. As patients were born erythroderm, 
the observed change in skin phenotypes from erythroderma into 
ichthyosis linearis circumflexa (ILC) in some patients is in line with 
previously described NS patients. Our cohort included less severely 
F I G U R E  2   Absolute numbers of B-cell 
subsets in healthy individuals and in adult 
patients with NS. A, Absolute numbers 
of naive and memory B-cell subsets and 
plasma cells. Columns indicate median 
values with interquartile range. B, 
Absolute numbers of IgE + memory B 
cells. Each symbol represents an individual 
with red lines indicating median values. 
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affected NS patients and half of our patients reported improvement 
of their skin with age (median age: 6.5 years). This might explain why 
less skin infections were reported in adults. We also hypothesized 
an impact of natural maturation of the immune system. In general, 
an increased susceptibility to infections during childhood has previ-
ously been described in healthy children, especially for respiratory 
infections and nasal immune responses in the first 2 years of life.39
Evaluation of atopic manifestations showed a remarkable high 
percentage of sensitization to food allergens, which is in line with 
previous observations.40 The increased risk of an atopic constitu-
tion corresponded to an elevated total IgE in 11 of the 12 tested 
patients as well as increased IgE+ memory B-cell numbers. Similar 
observations have been described in patients with atopic dermati-
tis.41 As described, the impaired epidermal skin barrier may open 
aberrant routes of entrance for allergens.42,43 Combined with a dif-
ferent local immune response with enhanced risk of Th2 imprint-
ing, this could lead to further sensitization to (food) allergens.20,42,44 
In our cohort food allergies for nuts, cow milk, eggs, and fish were 
most common. The types of allergens do not differ from the gen-
eral population in which 90% of the allergic responses to food are 
caused by cow's milk, soy, eggs, wheat, peanuts, tree nuts, fish, 
and shellfish.45-48 This suggests that the role of the skin barrier and 
subepithelial environment with an increased Th2 profile might be 
greater than assumed for the atopic constitution in NS. Although 
F I G U R E  3   Absolute numbers of 
T-cell subsets in healthy individuals and 
in adult patients with NS. A, of total 
CD8 + T cells and CD8 + Tnaive, Tcm, 
TemRO, and TemRA. B, Total CD4+ T 
cells and CD4 + Tnaive, Tcm, TemRO, and 
TemRA. Columns represent median values 
with interquartile range. C, Counts of 
regulatory T cells, Th1, Th2, and Th17 T 
cells. Each symbol represents an individual 
with red lines indicating median values. 
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Th2-cell numbers were not affected and we did not measure spe-
cific cytokines such as TSLP and TARC (thymus and activation-reg-
ulated chemokine), we speculate that Th2 cytokines are increased 
as well. In addition, possibly not only cell numbers but also balances 
between Th1/Th2 immunity are important which is in line with our 
observations which show significant lower Th1-cell numbers imply-
ing a disturbed Th1/Th2 balance. However, since NS patients display 
ichthyosis also a Th17/IL23 pathway could be involved.49
To our knowledge, this national cohort of 14 NS patients is the 
largest described until now.22,23,26,40,50-55 Because of active recruit-
ment, we assume less selection bias and greater diversity in severity 
in our cohort. For example, two patients were not in care before 
active recruitment and received their topical treatment from their 
general practitioner. Another strength is the multidisciplinary ap-
proach of this study. Evaluation of anamnestic information was par-
tially based on retrospective data and information on the type of 
microorganisms involved in previous infections was incomplete and 
can be considered as a limitation.
4.1 | Clinical implications
Evaluation of patients with Netherton syndrome in the Dutch co-
hort showed no evidence for a severe, clinically relevant systemic 
immunodeficiency. The syndrome more likely seems a severe skin 
disease due to a local impaired skin barrier with an increased risk 
of infections and sensitization to food allergens, combined with re-
duced maturation of the immune system at a young age.
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